Rubius

Optimizing cell engineering with a unified informatics platform

Creating cellular medicines from red blood cells

Rubius Therapeutics is genetically engineering red blood cell therapeutics, or RCTs, to treat a range of diseases. These RCTs are capable of targeting cancer through activating immunity, treating auto-immune diseases through self-antigen tolerance induction, and combating rare enzyme deficiencies by introducing therapeutic enzymes that are cellularly shielded.

Challenges

Collaborating with inaccessible data

Manual record keeping systems that housed all experimental data – including donor metadata, DNA stock, and prototype protein expression – were disorganized and cluttered, hindering cross-team collaboration.

Inefficient request fulfillment

Legacy request management protocols were inefficient and required scientists and managers to search through scattered, disparate records on cell cultures and quality control assays.

Difficulty tracking projects

Engineering processes were out of sync and difficult to track as a result of decentralized systems of information storage and unreliable reporting on project progress.

Outcomes

Cross-team collaboration with complete experimental context

Rubius stores, shares, and interlinks all the experimental data of their samples, vectors, and engineered red blood cells in Benchling. Now, Rubius effortlessly navigates from sequences to prototype backgrounds and experimental conditions.

Insightful request management

Rubius now streamlines their request fulfillment process, ultimately using this information to track experiment status and forecast needs in real-time.

Centralized project management

With Benchling Workflows, Rubius structures, executes on, and optimizes their cell engineering processes from DNA production to cell construction.

Learn about how we're transforming R&D operations for the better

Helix Image